Dilated cardiomyopathy Cell Models for Research

Dilated cardiomyopathy (DCM) is a leading cause of heart failure and a major indication for heart transplantation. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, with DCM contributing significantly to morbidity and mortality. The prevalence of DCM is estimated at 1 in 2500 individuals, but it may be higher due to underdiagnosis. The 5-year survival rate for DCM patients is approximately 50% after diagnosis, as reported by the National Cancer Institute (NCI) and other sources. Key risk factors include genetic mutations, viral infections, autoimmune diseases, and exposure to toxins such as alcohol and chemotherapy agents.

DCM is an ideal model for studying cardiac biology and disease mechanisms due to its well-defined genetic basis and the availability of patient-derived samples. The disease exhibits significant genetic heterogeneity, with over 60 genes implicated in familial cases. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the ClinVar database, provide valuable resources for studying genotype-phenotype correlations. Open questions remain regarding the precise molecular pathways that lead from genetic mutations to contractile dysfunction, making DCM a fertile ground for mechanistic studies.

DCM pathogenesis involves several key pathways that converge on cardiomyocyte function and survival:

• • Sarcomere dysfunction: Mutations in genes encoding sarcomeric proteins (e.g., MYH7, TNNT2) disrupt actin-myosin cross-bridge cycling, leading to impaired contractility.
• • Cytoskeletal and nuclear envelope defects: Mutations in LMNA and DES alter nuclear integrity and cytoskeletal organization, causing cellular fragility and apoptosis.
• • Calcium handling abnormalities: Mutations in PLN and RYR2 affect calcium homeostasis, leading to arrhythmias and contractile dysfunction.
• • Mitochondrial dysfunction: Mutations in mitochondrial genes or nuclear-encoded mitochondrial proteins impair energy production, contributing to cellular stress.

Data compiled from TCGA, COSMIC, and ClinVar.

DCM is characterized by deregulation of several signaling networks that are critical for cardiac function:

• • MAPK/ERK pathway: Overactivation of this pathway in response to stress leads to pathological hypertrophy and fibrosis.
• • PI3K/AKT pathway: Impaired signaling reduces cell survival and promotes apoptosis.
• • Wnt/β-catenin pathway: Aberrant activation contributes to fibrosis and remodeling.
• • Calcium/calcineurin/NFAT pathway: Dysregulated calcium signaling activates transcription factors that promote maladaptive gene expression.

Key nodes in these networks include growth factors, G-protein coupled receptors, and transcription factors such as MEF2 and GATA4.

Organoids derived from iPSCs offer a more physiologically relevant 3D model, allowing for the study of cell-cell interactions and tissue-level responses.

• • Genetic engineered mouse models (GEMM): Knock-in of specific mutations (e.g., LMNA H222P) recapitulates human DCM phenotypes.
• • Induced models: Administration of doxorubicin or pressure overload via transverse aortic constriction (TAC) induces DCM-like pathology.
• • Patient-derived xenografts (PDX): Not commonly used for DCM due to the lack of tumor tissue, but iPSC-derived cardiomyocytes can be transplanted into immunodeficient mice for in vivo studies.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise genetic modifications, providing powerful tools for studying DCM. Examples include:

• • TNNT2 R92W knock-in: This mutation is associated with familial DCM and can be introduced into iPSC-derived cardiomyocytes to study its effects on contractility.
• • LMNA knockout: Loss-of-function models help elucidate the role of lamin A/C in nuclear stability and gene regulation.
• • TTN truncation: Truncating variants are common in DCM; isogenic lines with TTN knockout or knock-in of a truncating mutation can be used to study sarcomere assembly.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing consistent and validated models, but it is essential to verify the genetic background and functional phenotype.

Gene-edited cell lines are instrumental in validating the pathogenicity of genetic variants. For example, introducing a specific mutation into a healthy cell line and observing a disease phenotype confirms its role. Conversely, correcting a mutation in patient-derived cells can rescue the phenotype, providing evidence for causality. This approach has been used to validate mutations in genes such as MYH7 and TNNT2.

Isogenic pairs (mutant vs. wild-type) are ideal for high-throughput drug screening. By comparing the response of mutant and control cells to a library of compounds, researchers can identify drugs that selectively target the mutant phenotype. This approach has been used to screen for compounds that improve contractility in TNNT2 mutant cardiomyocytes. Additionally, gene-edited cells can be used to study resistance mechanisms to existing therapies, such as beta-blockers.

CRISPR-based synthetic lethality screens can identify genes that are essential for the survival of DCM-affected cells but not normal cells. These genes may serve as novel therapeutic targets or biomarkers. For example, a screen in LMNA knockout cells might reveal a dependency on a specific DNA repair pathway, which could be targeted with a small molecule inhibitor.